Study Title | Study Sponsor | Status | Study Drug | Trial Phase | Study Protocol Number | Site |
---|---|---|---|---|---|---|
Induction Study #1 - A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn’s Disease. | Celgene | Ongoing | Ozanimod HCl | 3 | RPC01-3201 | KAUH-J |
Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma | SWOG (Southwest Oncology Group) | Ongoing | Ibrutinib | 3 | A051301 | KFSH&RC-R |
HELIOS-B: A Phase 3, Randomized, Doubleblind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with Cardiomyopathy) | Alnylam Pharmaceuticals. | Ongoing | ALN-TTRSC02 (Vutrisiran) | 3 | ALN-TTRSC02-003 | King Khalid University Hospital (Riyadh) |
Global Study to Assess the Addition of Bevacizumab to Carboplatin and Paclitaxel as Front-line Treatment of Epithelial Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Carcinoma | Roche | Completed | Bevacizumab | 3 | MO22923 | KFMC |
Freeze dried kale to go, new superfood supplement to reduce metabolic risk in Saudi subjects | The National Plan for Science,Technology and Innovation | Ongoing | Freeze dried kale | 3 | H-01-R-002 | King Khalid University Hospital (Riyadh) |
Follow-up of Phase I/II study of CaspaCIDe T cells (BPX-501) from an HLA-partially matched family donor after negative selection of TCR αβ+T cells in pediatric patients affected by hematological disorders | Bellicum Pharmaceuticals | Ongoing | Rimiducid | 1/2 | CT17-008-R | NGHA-R |
Fluids in Septic Shock: A Randomized control Trial | McMaster University | Completed | Sodium Chloride | 3 | 20120802 | King Fahad University Hospital (Al-Khobar) |
Fluids in Septic Shock (FISSH): a randomized controlled trial. | McMaster University | Ongoing | Normal Saline & Ringer's Lactate | 3 | 2211076 | King Faisal Specialist Hospital and Research Center (Riyadh) |
Extra-corporeal membrane oxygenation plus Tocilizimub in treatment of COVID-19 | KAIMRC | Ongoing | TOCILIZUMAB | 3 | RC20/225/R | King Abdulaziz Medical City NG (Riyadh) |
Extra-corporeal membrane oxygenation plus Tocilizimub in treatment of COVID-19 | KAIMRC | Ongoing | TOCILIZUMAB | 3 | RC20/225/R | King Abdulaziz Medical City NG (Riyadh) |